Sanjay Subramanian
CIK 1790246 · Chief Financial Officer · last filed 2026-09-11
Sanjay Subramanian is a Chief Financial Officer who has filed 27 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for SCYX, was dated Sep 11, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $128.1K across reported positions. 11 SEC filings were submitted jointly with Inozyme Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OCGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MALVERN, PA 19355
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SCYX | Chief Financial Officer | — | $3.79 | — | $0 | 1 | 2026-09-11 |
| Inozyme Pharma, Inc. (INZY) Delisted | SVP, CFO & Head of BD | 39,701 | $4.00 | $158.8K | $100.0K | 9 | 2025-06-27 |
| OCGN | Chief Financial Officer | 161,125 | $0.80 | $128.1K | -$1.16M | 16 | 2022-01-05 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-11 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2025-07-03 | — | Mixed | −39,701 | -$158.8K | |
| 2025-06-27 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +6,813 | $5.0K | EDGAR |
| 2025-04-02 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +2,490 | $1.9K | EDGAR |
| 2025-03-17 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-15 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-10-03 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +2,319 | $8.3K | EDGAR |
| 2023-04-04 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +979 | $2.2K | EDGAR |
| 2023-03-27 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-04-20 | Inozyme Pharma, Inc. (INZY) Delisted | Buy (P) | +27,100 | $100.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.